Elucidating Design Principles for Engineering Cell‐Derived Vesicles to Inhibit SARS‐CoV‐2 Infection

Mostrar otras versiones (1)

The ability of pathogens to develop drug resistance is a global health challenge. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) presents an urgent need wherein several variants of concern resist neutralization by monoclonal antibody (mAb) therapies and vaccine‐induced sera. Decoy nano...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunnels, Taylor F., Stranford, Devin M., Mitrut, Roxana E., Kamat, Neha P., Leonard, Joshua N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106922/
https://www.ncbi.nlm.nih.gov/pubmed/35388947
http://dx.doi.org/10.1002/smll.202200125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106922/
https://www.ncbi.nlm.nih.gov/pubmed/35388947
http://dx.doi.org/10.1002/smll.202200125

Ejemplares similares